Clinical Trial Update: A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of nivolumab with or without nab-paclitaxel in metastatic non-small cell lung cancer was terminated with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Carcinoma of Lung
• Non-small Cell Lung Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• nivolumab (nivolumab)

Snippet

Sponsor: Alliance Foundation Trials, LLC. | Conditions: Non-Small-Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4 | Phase 2 | Status: TERMINATED | Results posted: 2022-09-08